Pacira Pharmaceuticals Inc (PCRX) Given Consensus Recommendation of “Hold” by Brokerages

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has received a consensus recommendation of “Hold” from the twenty-three brokerages that are presently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $47.21.

Several brokerages have weighed in on PCRX. Needham & Company LLC lowered their target price on shares of Pacira Pharmaceuticals from $55.00 to $52.00 and set a “buy” rating for the company in a research note on Thursday, October 19th. BidaskClub raised shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Wedbush reaffirmed a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Friday, January 5th. HC Wainwright reaffirmed a “buy” rating and set a $52.00 target price on shares of Pacira Pharmaceuticals in a research note on Thursday, November 9th. Finally, Janney Montgomery Scott lowered shares of Pacira Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $27.00 target price for the company. in a research note on Thursday, October 26th.

Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) opened at $36.35 on Tuesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.99 and a quick ratio of 6.24. Pacira Pharmaceuticals has a 1-year low of $29.81 and a 1-year high of $58.95. The stock has a market cap of $1,480.00, a PE ratio of -27.75 and a beta of 1.88.

In other news, SVP James B. Jones sold 850 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $41.11, for a total value of $34,943.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO David M. Stack sold 58,885 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $38.34, for a total transaction of $2,257,650.90. Following the completion of the transaction, the chief executive officer now directly owns 159,164 shares of the company’s stock, valued at approximately $6,102,347.76. The disclosure for this sale can be found here. In the last three months, insiders sold 98,960 shares of company stock valued at $3,868,341. Insiders own 6.60% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Northern Trust Corp boosted its stake in shares of Pacira Pharmaceuticals by 9.1% in the second quarter. Northern Trust Corp now owns 505,529 shares of the company’s stock valued at $24,114,000 after purchasing an additional 42,289 shares during the period. State Street Corp raised its holdings in Pacira Pharmaceuticals by 1.0% in the second quarter. State Street Corp now owns 1,118,083 shares of the company’s stock valued at $53,340,000 after acquiring an additional 10,727 shares in the last quarter. Epoch Investment Partners Inc. raised its holdings in Pacira Pharmaceuticals by 195.7% in the third quarter. Epoch Investment Partners Inc. now owns 535,999 shares of the company’s stock valued at $20,127,000 after acquiring an additional 354,728 shares in the last quarter. Parametric Portfolio Associates LLC raised its holdings in Pacira Pharmaceuticals by 26.0% in the second quarter. Parametric Portfolio Associates LLC now owns 111,193 shares of the company’s stock valued at $5,304,000 after acquiring an additional 22,949 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its holdings in Pacira Pharmaceuticals by 41.2% in the third quarter. Rice Hall James & Associates LLC now owns 273,434 shares of the company’s stock valued at $10,267,000 after acquiring an additional 79,797 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2018/02/13/pacira-pharmaceuticals-inc-pcrx-given-consensus-recommendation-of-hold-by-brokerages.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply